The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
September 23, 2021
Leuprolide Acetate (Fensolvi) for Central Precocious Puberty (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Leuprolide Acetate (Fensolvi) for Central Precocious Puberty (online only)
September 23, 2021 (Issue: 1634)
Fensolvi (Tolmar), a long-acting subcutaneous formulation
of the gonadotropin-releasing hormone (GnRH)
agonist leuprolide acetate, has been approved by the
FDA for treatment of central precocious puberty (CPP)
in children ≥2 years old. It is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.